Three-Year Results of the IN.PACT SFA Japan Trial Comparing Drug-Coated Balloons With Percutaneous Transluminal Angioplasty.

Yoshimitsu Soga Osamu IidaKazushi UrasawaShigeru SaitoMichael R JaffHong WangHiroko OokuboHiroyoshi Yokoi

Published in: Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists (2020)

The final report of the IN.PACT SFA Japan trial showed that the IN.PACT Admiral DCB is safe and had durable outcomes through 3 years in Japanese participants with femoropopliteal occlusive disease.

Keyphrases

phase iii
study protocol
phase ii
clinical trial
randomized controlled trial
open label
radiofrequency ablation
sickle cell disease
type diabetes
metabolic syndrome
adipose tissue
insulin resistance
adverse drug